Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
NextCure, Inc. (NXTC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
8-K
| Quarterly results |
| 03/02/2023 |
8-K
| Quarterly results |
| 11/03/2022 |
8-K
| Quarterly results |
| 08/04/2022 |
8-K
| Quarterly results |
| 06/23/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 03/03/2022 |
8-K
| Quarterly results |
| 11/15/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting BELTSVILLE, Md. – November 13, 2021 -- NextCure, Inc. , a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced new data from two clinical studies and one research study presented at the Society for Immunotherapy of Cancer annual meeting in Washington, D.C., and on a virtual platform. The data come from clinical studies evaluating NC318, a Siglec-15 antibody, and NC410, a fusion protein of LAIR-2, in patients with advanced/metastatic solid tumors, as well as from a research study evaluating NC410’ s impact on T ce...",
"Investor presentation issued by NextCure, Inc." |
|
| 11/04/2021 |
8-K
| Quarterly results|
Docs:
|
"NEXTCURE, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Revenue: Revenue from former research and development arrangement $ — $ — $ — $ 22,378 Operating expenses: Research and development 13,597 12,740 37,928 34,448 General and administrative 4,911 4,659 15,766 12,918 Total operating expenses 18,508 17,399 53,694 47,366 Loss from operations Other income, net 578 1,032 1,244 3,846 Net loss $ $ $ $ Loss per share - basic and diluted $ $ $ $ Weighted-average shares outstanding - basic and diluted 27,615,038 27,547,737 27,607,685 27,524,350 Comprehensive loss: Net loss $ $ $ $ Unrealized gain on marketable securities 66 1,298 Total comprehensive loss $ $ $ $ NEXTCURE, INC. CONDENSED BALANCE..." |
|
| 10/04/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/24/2021 |
8-K
| Quarterly results |
| 08/05/2021 |
8-K
| Quarterly results |
| 06/25/2021 |
8-K
| Quarterly results |
| 05/06/2021 |
8-K
| Quarterly results |
| 03/04/2021 |
8-K
| Quarterly results |
| 02/24/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/14/2021 |
8-K
| Quarterly results |
| 09/14/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/31/2020 |
8-K
| Quarterly results |
| 07/17/2020 |
8-K
| Quarterly results |
| 07/13/2020 |
8-K
| Quarterly results |
| 06/11/2020 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 03/30/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/13/2020 |
8-K
| Termination of a Material Definitive Agreement |
| 12/02/2019 |
8-K
| Other Events |
| 10/02/2019 |
8-K
| Quarterly results |
| 08/08/2019 |
8-K
| Regulation FD Disclosure |
| 05/13/2019 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits |
|
|